In adults with type 2 diabetes and heart disease, tirzepatide is associated with a 16% lower risk of death from any cause over about four years compared to dulaglutide.
Mechanism
Synthesis from 1 study
Tirzepatide helps the body control blood sugar better and lose weight, which takes pressure off the heart and blood vessels. This makes serious heart problems less likely to happen, which is why fewer people died while taking it compared to the other drug.
Most probable mechanism
Tirzepatide helps the body use insulin better and lose weight, which lowers blood sugar and reduces strain on the heart and blood vessels, making it less likely for someone with diabetes and heart disease to die from heart or circulation problems.
Tirzepatide activates GLP-1 and GIP receptors, enhancing insulin secretion and suppressing glucagon release in response to meals
Improved insulin sensitivity and reduced hepatic glucose production lead to sustained lowering of blood glucose levels
Appetite suppression and delayed gastric emptying result in significant reduction in body weight and visceral adiposity
Reduced adiposity and improved metabolic profile decrease systemic inflammation, endothelial dysfunction, and cardiac workload
Lowered cardiovascular stress and metabolic burden reduce the incidence of fatal events such as heart attack, stroke, and heart failure
Evidence from Studies
Supporting (1)
Community contributions welcome
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.